How Recent Data Impacts Pancreatic Cancer Management

Integrity CE

M. Pishvaian

ESMO 2024 Summary: Updates in Pancreatic Cancer and Impacts on Pract…

2024 ESMO Annual Meeting Insights Hub

H. Babiker

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

Integrity CE

L. Zheng

Updates in Perioperative Therapy of Pancreatic Cancer

Horizon CME

P. Philip

NORPACT-1 Trial Updates: Neoadjuvant FOLFIRINOX vs. Upfront Surgery …

Yale Cancer Center

J. Lacy

Clinical Takeaways in From Recent Key Trials in Pancreatic Cancer

Hani Babiker

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

Integrity CE

W. Burns

ASCO® 2024 Insights: "Biomarker-Directed Treatment for Pancreatic Ad…

2024 ASCO® Annual Meeting Insights Hub

J. Knox

ASCO® 2024 Insights: "Summary of the PASS-01 Trial - 1L FOLFIRINOX v…

ecancer

J. Knox

ASCO® 2024 Insights: "EXPEL-PANC - A Ph2 Study of BXCL701 + Pembro i…

2024 ASCO® Annual Meeting Insights Hub

B. Weinberg

ESMO GI 2024 Insights: Role of Personalized Medicine in Pancreatic C…

Insights from 2024 ESMO GI Annual Meeting

T. Seufferlein

GI Oncology Year in Review: Precision Medicine Update in Metastatic …

Yale Cancer Center

J. Lacy

Perspectives on the Recent FDA Approval of NALIRIFOX in Frontline Me…

UCLA Health

Z. Wainberg

GI Oncology Year in Review: Metastatic Pancreatic Cancer - NAPOLI-3 …

Yale Cancer Center

J. Lacy

Updates in Nonmetastatic Upper-GI Adenocarcinoma

Integrity CE

J. Hernandez

ASCO® 2024 Insights: "Efficacy, Safety, and PD of CM24 With Nivo & C…

2024 ASCO® Annual Meeting Insights Hub

T. Macarulla

ASCO® 2023 Summary: "GI Expert Panel Discussion on Key Trials Includ…

Insights from 2023 ASCO® Annual Meeting

Y. Janjigian, S. Cytryn, S. Maron

Precision Medicine in GI Cancers

Fred Hutchinson Cancer Center

D. Zhen

Year in Review: Pancreatic Cancers

OncoAlert

M. Lewis

FDA Approval of Liposomal Irinotecan/NALIRIFOX in 1L Metastatic Panc…

Shubham Pant